Evidence map›Paper›PMID 26962229›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2016

KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV.

Jeanette E Boudreau, Tiernan J Mulrooney, Jean-Benoît Le Luduec, Edward Barker, Katharine C Hsu

Open access · greenAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 124 citations in OpenAlex.

  1. Trial
  2. NK Cell Activity and CD57Frontiers in immunology · 2020
    Trial
  3. Trial
  4. Article
  5. Article
  6. CD56bioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jeanette E BoudreauImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065;ORCID http://orcid.org/0000-0002-9187-7128
Tiernan J MulrooneyImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065;ORCID http://orcid.org/0000-0002-0218-2771
Jean-Benoît Le LuduecImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065;
Edward BarkerDepartment of Immunology and Microbiology, Rush University Medical Center, Chicago, IL 60612;
Katharine C HsuImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065; and Weill Cornell Medical College, New York, NY 10065 hsuk@mskcc.org.
Memorial Sloan Kettering Cancer Center · USRush University Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAMER, ERIC G. · 1985 to 2023
$59.0M
Hematopopietic Stem Cell TransplantationU01AI069197 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2005 to 2026
$18.9M
Vpu inhibits NK cell function through down regulation of NTB-AR01AI065361 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI BARKER, EDWARD · 2006 to 2016
$2.9M
NK Tolerance and Hematopoietic Cell TransplantationR01HL088134 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C · 2008 to 2012
$2.1M
NCI NIH HHS P01 CA023766NCI NIH HHS P01 CA23766NCI NIH HHS P03 CA008748NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA008748-46NHLBI NIH HHS R01 HL088134NIAID NIH HHS R01 AI065361NIAID NIH HHS U01 AI069197
6 · The paper itself

Abstract

NK cells recognize self-HLA via killer Ig-like receptors (KIR). Homeostatic HLA expression signals for inhibition via KIR, and downregulation of HLA, a common consequence of viral infection, allows NK activation. Like HLA, KIR are highly polymorphic, and allele combinations of the most diverse receptor-ligand pair, KIR3DL1 and HLA-B, correspond to hierarchical HIV control. We used primary cells from healthy human donors to demonstrate how subtype combinations of KIR3DL1 and HLA-B calibrate NK education and their consequent capacity to eliminate HIV-infected cells. High-density KIR3DL1 and Bw4-80I partnerships endow NK cells with the greatest reactivity against HLA-negative targets; NK cells exhibiting the remaining KIR3DL1/HLA-Bw4 combinations demonstrate intermediate responsiveness; and Bw4-negative KIR3DL1(+) NK cells are poorly responsive. Cytotoxicity against HIV-infected autologous CD4(+) T cells strikingly correlated with reactivity to HLA-negative targets. These findings suggest that the programming of NK effector function results from defined features of receptor and ligand subtypes. KIR3DL1 and HLA-B subtypes exhibit an array of binding strengths. Like KIR3DL1, subtypes of HLA-Bw4 are expressed at distinct, predictable membrane densities. Combinatorial permutations of common receptor and ligand subtypes reveal binding strength, receptor density, and ligand density to be functionally important. These findings have immediate implications for prognosis in patients with HIV infection. Furthermore, they demonstrate how features of KIR and HLA modified by allelic variation calibrate NK cell reactive potential.

Indexed as

CD4-Positive T-LymphocytesCells, CulturedHIV-1HIV InfectionsHLA-B AntigensHumansKiller Cells, NaturalLymphocyte ActivationReceptors, KIR3DL1HLA-B AntigensHLA-Bw4 antigenKIR3DL1 protein, humanReceptors, KIR3DL1

Identifiers

PMID26962229
PMCPMC4868784
OpenAlexW2296584843

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.